Takeda TAK · NYSE
$19.69 +1.23% (+$0.24)
Summary
46 / 100 · Bulios Score
What speaks for it
- Out of every 100 JPY of revenue, 12 JPY is left as free cash.
- It has been profitable 6 years in a row.
What to watch
- It pays out more in dividends than it earns: 171% of profit.
- You pay 53.8 JPY for 1 JPY of yearly profit, a lot for its sector.
- Earnings per share fell by 14% a year over the last 3 years.
- Operating profit covers the interest on its debt only 1.9 times.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 53.8 JPY for 1 JPY of yearly profit. Over the last five years it was 40.9 JPY on average.
Valuation in detailIs it growing?
SlowlyRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 8.4% a year over 5 years. Over the last 3 years it grew by 5.9% a year. For the next fiscal year analysts expect revenue to fall by 1.9%. Earnings per share fell by 14% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 JPY of revenue goes
- Cost of sales 41 JPY
- Research and development 15 JPY
- Sales and administration 33 JPY
- Taxes and other 7.1 JPY
- Net profit 3.9 JPY
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 JPY
Out of every 100 JPY of revenue, 3.9 JPY is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 8.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 3.19%
- Paid out of profit
- 171%
- Raised in a row
- 1 year
You receive $0.62 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 5
- Hold 1
- Sell 0
No analyst has published a price target.
83% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Gastroenterology 31%
- PDT Immunology 23%
- Rare Diseases 17%
- Oncology 13%
- Neuroscience 9.2%
- Other 6.3%
By region
- UNITED STATES 49%
- Europe And Canada 26%
- JAPAN 9.8%
- Latin America 5.7%
- CHINA 4.4%
- Other 5.3%
Gastroenterology brings in 31% of revenue. PDT Immunology grew fastest, by 20% a year.
Segments in detail